Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting?

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Evidence-Based Medicine

Background:

• Coronary artery bypass grafting (CABG) is a common cardiac surgery.
• Thrombotic complications remain a significant concern post-CABG, particularly in high-risk patients.
• Optimal antiplatelet therapy strategies after CABG are crucial for improving outcomes.

Purpose of the Study:

• To evaluate the efficacy of adding clopidogrel to aspirin for preventing thrombotic complications in high-risk patients post-coronary bypass surgery.
• To synthesize best evidence from guidelines and studies to inform clinical practice.
• To determine the recommended duration of dual antiplatelet therapy.

Main Methods:

• A structured best evidence topic review was conducted.
• Searched 511 papers, including major international guidelines.
• Eleven papers provided the best evidence for analysis.

Main Results:

• The 2004 American College of Chest Physicians (ACC) guidelines recommend 9-12 months of clopidogrel plus aspirin for CABG patients with non-ST segment elevation acute coronary syndrome.
• Subanalyses of CURE and CAPRIE studies showed reduced death, myocardial infarction, and stroke in CABG patients on dual therapy.
• High-risk patients include those with recent myocardial infarction or indwelling stents.

Conclusions:

• Dual antiplatelet therapy with aspirin and clopidogrel for 9-12 months is recommended for high-risk patients post-CABG.
• This includes patients with recent non-ST segment elevation myocardial infarction or uncovered stents.
• Further randomized trials are ongoing to confirm these findings.